<DOC>
	<DOCNO>NCT00521183</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Drugs , cytochlor tetrahydrouridine , may make tumor cell sensitive radiation therapy . PURPOSE : This phase I trial study side effect best dose cytochlor give together tetrahydrouridine external-beam radiation therapy treat patient cancer spread brain .</brief_summary>
	<brief_title>Cytochlor , Tetrahydrouridine , External-Beam Radiation Therapy Treating Patients With Cancer That Has Spread Brain</brief_title>
	<detailed_description>OBJECTIVES : Primary - Establish safety toxicity profile cytochlor H4U give combination external-beam radiotherapy 2 week treatment drug alone previous week . Secondary - Determine effectiveness H4U inhibit systemic cytidine deaminase ( CD ) course treatment cytochlor H4U . - Perform detailed pharmacokinetic study determine level cytochlor metabolite serum urine week 1 , 2 , 3 treatment . OUTLINE : This dose-escalation study cytochlor . Patients receive cytochlor IV tetrahydrouridine ( H4U ) IV 5 minute 3 day week 1 day 1-5 week 2 3 . Patients also undergo external-beam radiotherapy 5 day week week 2 3 initiated 3-4 hour infusion cytochlor H4U . Treatment may repeat absence disease progression unacceptable toxicity . After completion study treatment , patient follow monthly 3 month , every 3 month 1 year , every 4 month 1 year , every 6 month 1 year , yearly thereafter .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Tetrahydrouridine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis metastatic cancer brain contrastenhanced MRI CT scan Eligible wholebrain radiotherapy ( WBRT ) Patients treat prior surgery eligible WBRT use post operatively Not plan treat stereotactic radiosurgery No leptomeningeal metastasis document contrastenhanced MRI/CT scan cerebrospinal fluid evaluation PATIENT CHARACTERISTICS : Inclusion criterion : Karnofsky performance status ( PS ) 70100 % ECOG PS 01 Leukocytes ≥ 3,000/µL Absolute neutrophil count &gt; 1,500/µL Platelet count &gt; 100,000/µL Total bilirubin normal AST ALT &lt; 2.5 time upper limit normal Creatinine normal OR creatinine clearance &gt; 60 mL/min Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ) prior study entry duration study participation Exclusion criterion : Uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness/social situation would limit compliance study requirement Pregnant lactate Alcohol dependence PRIOR CONCURRENT THERAPY : No prior radiotherapy brain No concurrent combination antiretroviral therapy HIVpositive patient No concurrent chemotherapy , immunotherapy , hormonal therapy ( exclude contraceptive replacement steroid ) , experimental medication No concurrent anticancer therapy outside protocol Systemic therapy one month brain radiotherapy allow No concurrent heparin coumadin</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>adult tumor metastatic brain</keyword>
</DOC>